Inovio Pharmaceuticals (FRA:GBM) Cyclically Adjusted FCF per Share: €-9.55 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GBM Inovio Pharmaceuticals Inc FRA:GBM
48 GF Score
Price €1.03
GF Value €0.17
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Cyclically Adjusted FCF per Share?

Inovio Pharmaceuticals FRA:GBM -4.91% 48 Cyclically Adjusted FCF per Share is €-9.55 as of Jun. 2026. GuruFocus rates FRA:GBM with a GF Score™ of 48/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Inovio Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.192. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-9.55 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -1.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -3.90% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Inovio Pharmaceuticals was 23.40% per year. The lowest was -9.00% per year. And the median was 4.10% per year.

As of today (2026-08-24), Inovio Pharmaceuticals's current stock price is €1.027. Inovio Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-9.55. Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Inovio Pharmaceuticals  (FRA:GBM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Inovio Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Inovio Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.22 -10.07 -10.20 -10.86 -9.11

Inovio Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.80 -9.84 -9.11 -9.19 -9.55

FRA:GBM vs TELO, ELTX, ALPS: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


FRA:GBM
48GF Score
Inovio Pharmaceuticals Inc FRA:GBM
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Inovio Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.192/333.9520*333.9520
=-0.192

Current CPI (Jun. 2026) = 333.9520.

Inovio Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -2.770 241.428 -3.832
201612 -2.299 241.432 -3.180
201703 -2.418 243.801 -3.312
201706 -3.082 244.955 -4.202
201709 -2.416 246.819 -3.269
201712 -1.660 246.524 -2.249
201803 -1.477 249.554 -1.977
201806 -2.194 251.989 -2.908
201809 -2.759 252.439 -3.650
201812 -1.934 251.233 -2.571
201903 -3.607 254.202 -4.739
201906 -2.599 256.143 -3.389
201909 -2.954 256.759 -3.842
201912 -1.492 256.974 -1.939
202003 -2.230 258.115 -2.885
202006 -1.859 257.797 -2.408
202009 -4.355 260.280 -5.588
202012 -2.949 260.474 -3.781
202103 -2.643 264.877 -3.332
202106 -3.739 271.696 -4.596
202109 -2.263 274.310 -2.755
202112 -1.922 278.802 -2.302
202203 -3.080 287.504 -3.578
202206 -2.438 296.311 -2.748
202209 -3.279 296.808 -3.689
202212 -1.643 296.797 -1.849
202303 -1.603 301.836 -1.774
202306 -1.355 305.109 -1.483
202309 -1.219 307.789 -1.323
202312 -1.060 306.746 -1.154
202403 -1.137 312.332 -1.216
202406 -0.979 314.175 -1.041
202409 -0.879 315.301 -0.931
202412 -0.626 315.605 -0.662
202503 -0.645 319.799 -0.674
202506 -0.465 322.561 -0.481
202509 -0.353 324.800 -0.363
202512 -0.268 324.054 -0.276
202603 -0.270 330.213 -0.273
202606 -0.192 333.952 -0.192

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-9.55 mean?
Inovio Pharmaceuticals (FRA:GBM) has a Cyclically Adjusted FCF per Share of €-9.55 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Inovio Pharmaceuticals' current Cyclically Adjusted FCF per Share is €-9.55. Overall, Inovio Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Cyclically Adjusted FCF per Share compare to TELO and ELTX?
Inovio Pharmaceuticals' Cyclically Adjusted FCF per Share of €-9.55 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Cyclically Adjusted FCF per Share is €-9.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (FRA:GBM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €1.03 — trading 504.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-9.55. Inovio Pharmaceuticals' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Inovio Pharmaceuticals (FRA:GBM), the current Cyclically Adjusted FCF per Share is €-9.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (FRA:GBM) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of €1.03 is trading 504.1% above its estimated GF Value™ of €0.17. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:GBM:

  • Cyclically Adjusted FCF per Share: €-9.55
  • GF Value™: €0.17 vs. price of €1.03 (504.1% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the FRA:GBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inovio Pharmaceuticals Business Description

Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
48GF Score

Get the complete analysis for FRA:GBM

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.03
Price
€0.17
GF Value